60079-22-3

Usage

Uses

Used in Pharmaceutical Industry:
2-[(3-aMino-3-carboxy-propanoyl)aMino]butane is used as a ligand in targeting SDF-1/CXCL12, a chemokine that plays a crucial role in various biological processes such as cell migration, proliferation, and survival. By targeting SDF-1/CXCL12, 2-[(3-aMino-3-carboxy-propanoyl)aMino]butane can potentially be used in the development of drugs that prevent the activation of CXCR4, a receptor involved in various diseases including cancer and autoimmune disorders.
The use of β-Aspartyl aspartic acid in structure-based drug design allows for the development of targeted therapies that can specifically interact with the desired receptors, leading to more effective treatments with fewer side effects. This approach can be particularly useful in the treatment of diseases where traditional therapies have limited efficacy or cause significant side effects.

InChI:InChI=1/C8H12N2O7/c9-3(7(14)15)1-5(11)10-4(8(16)17)2-6(12)13/h3-4H,1-2,9H2,(H,10,11)(H,12,13)(H,14,15)(H,16,17)

Upstream product

• 3130-87-8 ASPARAGINE 
• 70-47-3 L-asparagine 
• 56-81-5 glycerol 
• 7732-18-5 water 
• 104870-26-0 N-(O-benzyl-N-benzyloxycarbonyl-L-β-aspartyl)-L-aspartic acid dibenzyl ester 

Relevant academic research and scientific papers

Aspartic acid condensate and a method for the preparation of (by machine translation)

The present invention relates to the field of organic synthesis technology, in particular to a kind of aspartic acid condensate preparation method, the preparation method comprises the following steps : (1) aspartic acid with alcohol to undergo esterification reaction, asparagic acid diester is obtained ; (2) Boc-L-aspartic acid-1-benzyl ester with aspartic acid diester reaction, the condensation product obtained ; (3) hydrolysis of the condensation product, the condensation states the asparagus acid is obtained. The invention uses of aspartic acid and Boc-L-aspartic acid-1-benzyl ester as the raw material, by esterification, condensation, hydrolysis, separation and purification to obtain high-purity aspartic acid condensate. The preparation method is suitable for laboratory in the preparation of large quantities, the impurity removal effect is good in the purification process. (by machine translation)

Isolation and identification of urinary β-aspartyl dipeptides and their concentrations in human urine

β-Aspartyl-methionine, -aspartic acid and -glutamic acid and γ-glutamyl-threonine and -glycine were isolated and identified in human urine by means of ion-exchange chromatography, highvoltage paper electrophoresis, acid hydrolysis and determination of N-terminal amino acids of the isolated compounds, and comparison of their behaviors in paper electrophoresis and chromatography with those of the authentic compounds. The concentrations of acidic β-aspartyl dipeptides in human urine were determined using an amino acid analyzer. Their concentrations were as follows: β-aspartyl-glycine, male, 44.4±8.5, female, 61.4±18.9, child, 83.7±27.1; -alanine, male, 11.0±4.9, female, 20.7±12.0, child, 25.3±9.1; -glutamic acid, male, 10.0±3.7, female, 23.0±8.5, child, 20.4±7.5; -serine, male, 9.9±2.8, female, 13.6±3.8, child, 14.9±4.7; -aspartic acid, male, 4.3±1.0, female, 9.1±2.2, child, 18.4±6.5; -threonine, male, 3.9±0.9, female, 5.8±1.1, child, 13.2±4.9 μmol/g creatinine (mean ± S.D.). The order of the sum of their concentrations tended to be child>female>male. Patients receiving intravenous hyperalimentation also excreted acidic β-aspartyl dipeptides into urine in amounts similar to those in females and in a pattern similar to that observed in healthy persons. This finding indicates that urinary β-aspartyl dipeptides were probably of endogenous origin because oral nutrition was stringently excluded in these patients.